The promiscuity of ARF interactions with the proteasome

FEBS Letters

Volumn 582, Issue 23-24, 2008, Pages 3257-3262

  Pollice, Alessandra ^a   Vivo, Maria ^a   Mantia, Girolama La ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cell stress sensor; p14 p19ARF; Proteasome; REG ; TBP 1 PSMC3

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2D; PROTEASOME; PROTEIN P14; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TUMOR SUPPRESSOR PROTEIN;

EUKARYOTIC CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; UBIQUITINATION;

ANIMALS; HUMANS; MICE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF;

MAMMALIA;

EID: 53049106860     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.09.026     Document Type: Short Survey

References (69)

1. Lowe S.W., and Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13 (2003) 77-83
2. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6 (2006) 663-673
3. Eymin B., Claverie P., Salon C., Leduc C., Col E., Brambilla E., Khochbin S., and Gazzeri S. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol. Cell Biol. 26 (2006) 4339-4350
4. Fatyol K., and Szalay A.A. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J. Biol. Chem. 276 (2001) 28421-28429
5. Garcia M.A., et al. Antiviral action of the tumor suppressor ARF. EMBO J. 25 (2006) 4284-4292
6. Menendez S., Khan Z., Coomber D.W., Lane D.P., Higgins M., Koufali M.M., and Lain S. Oligomerization of the human ARF tumor suppressor and its response to oxidative stress. J. Biol. Chem. 278 (2003) 18720-18729
7. Pollice A., Nasti V., Ronca R., Vivo M., Lo Iacono M., Calogero R., Calabro V., and La Mantia G. Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1. J. Biol. Chem. 279 (2004) 6345-6353
8. Pollice A., Sepe M., Villella V.R., Tolino F., Vivo M., Calabro V., and La Mantia G. TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation. Oncogene 26 (2007) 5154-5162
9. Takaoka A., et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (2003) 516-523
10. Adams. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4 (2004) 349-360
11. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 425-479
12. Asher G., Tsvetkov P., Kahana C., and Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 19 (2005) 316-321
13. Jariel-Encontre I P.M., Martin F., Carillo S., Salvat C., and Piechaczyk M. Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26S proteasome. J. Biol. Chem. 270 (1995) 11623-11627
14. Kalejta R.F., and Shenk T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl. Acad. Sci. USA 100 (2003) 3263-3268
15. Ma C.P., Slaughter C.A., and DeMartino G.N. Identification, purification, and characterization of a protein activator (PA28) of the 20S proteasome (macropain). J. Biol. Chem. 267 (1992) 10515-10523
16. Realini C., Jensen C.C., Zhang Z., Johnston S.C., Knowlton J.R., Hill C.P., and Rechsteiner M. Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. J. Biol. Chem. 272 (1997) 25483-25492
17. Barton L.F., Runnels H.A., Schell T.D., Cho Y., Gibbons R., Tevethia S.S., Deepe Jr. G.S., and Monaco J.J. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J. Immunol. 172 (2004) 3948-3954
18. Murata S., Kawahara H., Tohma S., Yamamoto K., Kasahara M., Nabeshima Y., Tanaka K., and Chiba T. Growth retardation in mice lacking the proteasome activator PA28gamma. J. Biol. Chem. 274 (1999) 38211-38215
19. Zannini L., et al. REGgamma proteasome activator is involved in the maintenance of chromosomal stability. Cell Cycle 7 (2008) 504-512
20. Kuo M.L., den Besten W., Bertwistle D., Roussel M.F., and Sherr C.J. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 18 (2004) 1862-1874
21. Rodway H., Llanos S., Rowe J., and Peters G. Stability of nucleolar versus non-nucleolar forms of human p14(ARF). Oncogene 23 (2004) 6186-6192
22. Chen X., Barton L.F., Chi Y., Clurman B.E., and Roberts J.M. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol. Cell. 26 (2007) 843-852
23. Li C., Wu R.C., Amazit L., Tsai S.Y., Tsai M.J., and O'Malley B.W. Specific amino acid residues in the basic helix-loop-helix domain of SRC-3 are essential for its nuclear localization and proteasome-dependent turnover. Mol. Cell. Biol. 27 (2007) 1296-1308
24. Zhou P. REGgamma: a shortcut to destruction. Cell 124 (2006) 256-257
25. Ben-Saadon R., Fajerman I., Ziv T., Hellman U., Schwartz A.L., and Ciechanover A. The tumor suppressor protein p16(INK4a) and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysine-less proteins that are degraded by the ubiquitin system. Direct evidence for ubiquitination at the N-terminal residue. J. Biol. Chem. 279 (2004) 41414-41421
26. Kuo M.L., den Besten W., and Sherr C.J. N-Terminal polyubiquitination of the ARF tumor suppressor, a natural lysine-less protein. Cell Cycle 3 (2004) 1367-1369
27. Li X., et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 124 (2006) 381-392
28. Corn P.G., McDonald III E.R., Herman J.G., and El-Deiry W.S. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat. Genet. 35 (2003) 229-237
29. Brusselmans K., Compernolle V., Tjwa M., Wiesener M.S., Maxwell P.H., Collen D., and Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J. Clin. Invest. 111 (2003) 1519-1527
30. Gonzalez F., Delahodde A., Kodadek T., and Johnston S.A. Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 296 (2002) 548-550
31. Ottosen S., Herrera F.J., and Triezenberg S.J. Transcription. Proteasome parts at gene promoters. Science 296 (2002) 479-481
32. Russell S.J., Reed S.H., Huang W., Friedberg E.C., and Johnston S.A. The 19S regulatory complex of the proteasome functions independently of proteolysis in nucleotide excision repair. Mol. Cell. 3 (1999) 687-695
33. Barak O., Aronheim A., and Shaul Y. HBV X protein targets HIV Tat-binding protein 1. Virology 283 (2001) 110-120
34. Lassot I., et al. The proteasome regulates HIV-1 transcription by both proteolytic and nonproteolytic mechanisms. Mol. Cell 25 (2007) 369-383
35. Park B.W., O'Rourke D.M., Wang Q., Davis J.G., Post A., Qian X., and Greene M.I. Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases. Proc. Natl. Acad. Sci. USA 96 (1999) 6434-6438
36. Brooks P., et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem. J. 346 Pt 1 (2000) 155-161
37. Shibatani T., Carlson E.J., Larabee F., McCormack A.L., Fruh K., and Skach W.R. Global organization and function of mammalian cytosolic proteasome pools: implications for PA28 and 19S regulatory complexes. Mol. Biol. Cell 17 (2006) 4962-4971
38. Rivett A.J., Bose S., Brooks P., and Broadfoot K.I. Regulation of proteasome complexes by gamma-interferon and phosphorylation. Biochimie 83 (2001) 363-366
39. Barnes C.J., Li F., Talukder A.H., and Kumar R. Growth factor regulation of a 26S proteasomal subunit in breast cancer. Clin. Cancer Res. 11 (2005) 2868-2874
40. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., and Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95 (1998) 8292-8297
41. Pomerantz J., et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92 (1998) 713-723
42. Stott F.J., et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17 (1998) 5001-5014
43. Zhang Y., Xiong Y., and Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92 (1998) 725-734
44. Eymin B., Karayan L., Seite P., Brambilla C., Brambilla E., Larsen C.J., and Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20 (2001) 1033-1041
45. Datta A., et al. ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF. Mol. Cell. Biol. 25 (2005) 8024-8036
46. Datta A., Nag A., Pan W., Hay N., Gartel A.L., Colamonici O., Mori Y., and Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J. Biol. Chem. 279 (2004) 36698-36707
47. Calabro V., Mansueto G., Santoro R., Gentilella A., Pollice A., Ghioni P., Guerrini L., and La Mantia G. Inhibition of p63 transcriptional activity by p14ARF: functional and physical link between human ARF tumor suppressor and a member of the p53 family. Mol. Cell. Biol. 24 (2004) 8529-8540
48. Kalinichenko V.V., et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 18 (2004) 830-850
49. Korgaonkar C., Hagen J., Tompkins V., Frazier A.A., Allamargot C., Quelle F.W., and Quelle D.E. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 25 (2005) 1258-1271
50. Gargano B., Fiorillo M., Amente S., Majello B., and Lania L. p14(ARF) is capable of promoting HIV-1 Tat degradation. Cell Cycle 7 (2008)
51. Huang Y., Wu M., and Li H.Y. Tumor suppressor ARF promotes non-classic proteasome-independent polyubiquitination of COMMD1. J. Biol. Chem. 283 (2008) 11453-11460
52. Karayan L., Riou J.F., Seite P., Migeon J., Cantereau A., and Larsen C.J. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 20 (2001) 836-848
53. Woods Y.L., Xirodimas D.P., Prescott A.R., Sparks A., Lane D.P., and Saville M.K. p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase. J. Biol. Chem. 279 (2004) 50157-50166
54. Chen D., Kon N., Li M., Zhang W., Qin J., and Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121 (2005) 1071-1083
55. Rizos H., Woodruff S., and Kefford R.F. p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle 4 (2005) 597-603
56. Paliwal S., Pande S., Kovi R.C., Sharpless N.E., Bardeesy N., and Grossman S.R. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol. Cell. Biol. 26 (2006) 2360-2372
57. Tago K., Chiocca S., and Sherr C.J. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc. Natl. Acad. Sci. USA 102 (2005) 7689-7694
58. Xirodimas D.P., Chisholm J., Desterro J.M., Lane D.P., and Hay R.T. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett. 528 (2002) 207-211
59. Liu X., et al. Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc. Natl. Acad. Sci. USA 104 (2007) 9679-9684
60. Datta A., Nag A., and Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol. Cell. Biol. 22 (2002) 8398-8408
61. Martelli F., et al. p19ARF targets certain E2F species for degradation. Proc. Natl. Acad. Sci. USA 98 (2001) 4455-4460
62. Rizos H., Scurr L.L., Irvine M., Alling N.J., and Kefford R.F. p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism. Cell Cycle 6 (2007) 1741-1747
63. Bertwistle D., Sugimoto M., and Sherr C.J. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 24 (2004) 985-996
64. Itahana K., Bhat K.P., Jin A., Itahana Y., Hawke D., Kobayashi R., and Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12 (2003) 1151-1164
65. Enomoto T., Lindstrom M.S., Jin A., Ke H., and Zhang Y. Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J. Biol. Chem. 281 (2006) 18463-18472
66. Colombo E., et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 66 (2006) 3044-3050
67. Zhang Q., Yoshimatsu Y., Hildebrand J., Frisch S.M., and Goodman R.H. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 115 (2003) 177-186
68. Bres V., et al. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat. Cell Biol. 5 (2003) 754-761
69. Lim K.L., et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 25 (2005) 2002-2009